Skip to main content Back to Top
Advertisement

10/8/2020

Fluticasone Propionate Oral Inhalers

Products Affected - Description

    • Flovent HFA inhalation aerosol, GlaxoSmithKline, 110 mcg/1 actuation, 12 gram metered dose inhaler, 1 count, NDC 00173-0719-20
    • Flovent HFA inhalation aerosol, GlaxoSmithKline, 220 mcg/1 actuation, 12 gram metered dose inhaler, 1 count, NDC 00173-0720-20
    • Flovent HFA inhalation aerosol, GlaxoSmithKline, 44 mcg/1 actuation, 10.6 gram metered dose inhaler, 1 count, NDC 00173-0718-20

Reason for the Shortage

    • GlaxoSmithKline is allocating Flovent HFA inhalers to wholesale customers in an effort to ensure equitable distribution of available product. Customers must place orders through their wholesalers.
    • GlaxoSmithKline has Flovent Diskus dry powder inhalers available.
    • GlaxoSmithKline is the sole supplier of fluticasone propionate inhalers.

Available Products

    • Flovent Diskus inhalation powder, GlaxoSmithKline, 100 mcg/blister, Institutional pack, dry powder inhaler, 28 blisters, 1 count, NDC 00173-0602-00
    • Flovent Diskus inhalation powder, GlaxoSmithKline, 100 mcg/blister, dry powder inhaler, 60 blisters, 1 count, NDC 00173-0602-02
    • Flovent Diskus inhalation powder, GlaxoSmithKline, 250 mcg/blister, Institutional pack, dry powder inhaler, 28 blisters, 1 count, NDC 00173-0601-00
    • Flovent Diskus inhalation powder, GlaxoSmithKline, 250 mcg/blister, dry powder inhaler, 60 blisters, 1 count, NDC 00173-0601-02
    • Flovent Diskus inhalation powder, GlaxoSmithKline, 50 mcg/blister, dry powder inhaler, 60 blisters, 1 count, NDC 00173-0600-02

Estimated Resupply Dates

    • GlaxoSmithKline has Flovent HFA aerosol inhalers on allocation.

Updated

Updated October 8, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 30, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.